Talk
Solving the R&D efficiency conundrum within Drug Discovery: Thoughts, Insights and Solutions
In this interactive panel discussion, five industry experts share their experience on topics such as promising technologies and applications in the field, how CRISPR/Cas9 can be used alongside other methods to enhance drug development and the advances and challenges of cell models in drug discovery.
Explore our cell identity coding platform
In this interactive panel discussion, five industry experts share their experience on topics such as promising technologies and applications in the field, how CRISPR/Cas9 can be used alongside other methods to enhance drug development and the advances and challenges of cell models in drug discovery.
Listen to experienced industry panellists engage in a thought-provoking discussion relating to new technologies within drug discovery.
Panellists
Kam Dhaliwal | SVP Alliance Management | bit.bio (chair)
Steve Rees | Vice President Discovery Biology | AstraZeneca
Benedict Cross | Chief Technology Officer | PhoreMost Ltd
Tilmann Buerckstuemmer | Chief Scientific Officer | Aelian Biotechnology GmbH
Marijn Vlaming | Head of Biology | Beerse & Leiden | Charles River Laboratories
bit.bio panel discussion at ELRIG Drug Discovery Digital
2020